Inhibitory effect of the cree traditional medicine wiishichimanaanh (Vaccinium vitis-idaea) on advanced glycation endproduct formation: Identification of active principles

Phytotherapy Research

Volumn 24, Issue 5, 2010, Pages 741-747

  Beaulieu, Louis Philippe ^a,b   Harris, Cory S ^a,b,c   Saleem, Ammar ^a,b   Cuerrier, Alain ^a   Haddad, Pierre S ^a   Martineau, Louis C ^a   Bennett, Steffany A L ^a,c   Arnason, John T ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Diabetic complications; Flavonoids; Lingonberry; Medicinal plants; Mountain cranberry; N (carboxymethyl)lysine; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CATECHIN; CYANIDIN 3 GLUCOSIDE; HYPERIN; PARA COUMARIC ACID; PLANT EXTRACT; UNCLASSIFIED DRUG; VACCINIUM VITIS IDAEA EXTRACT;

ARTICLE; DRUG EFFECT; NONHUMAN; TRADITIONAL MEDICINE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLAVONOIDS; FRUIT; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; MEDICINE, TRADITIONAL; PHENOLS; PLANT EXTRACTS; VACCINIUM VITIS-IDAEA;

VACCINIUM ERYTHROCARPUM; VACCINIUM VITIS-IDAEA;

EID: 77952069400     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3025     Document Type: Article

References (45)

1. Baynes JW, Thorpe SR. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9. (Pubitemid 29019345)
2. Blumenthal M. 1998. The complete German commision E monographs - Therapeutic guide to herbal medicines. American Botanical Council: Austin, TX.
3. Chambers BK, Camire ME. 2003. Can cranberry supplementation benefit adults with type 2 diabetes? Diabetes Care 26: 2695-2696.
4. Cheng H-Y, Lin T-C, Yang C-M, Shieh D-E, Lin C-C. 2005. In vitro anti-HSV-2 activity and mechanism of action of proanthocyanidin A-1 from Vaccinium vitis-idaea. J Sci Food Agric 85: 10-15.
5. Cuerrier A, Aînés de Kangirsujuq, Q, 2005. Le savoir botanique des Inuits de Kangirsujuaq, Nunavik 4e éd. Étude effectuée pour l'Administration régionale Kativik. Institut culturel Avataq & Institut de recherche en biologie végétale: Montreal; 67.
6. Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR, Lyons TJ, Baynes JW. 1991. The Maillard reaction in vivo. Z Ernahrungswiss 30: 29-45.
7. Ek S, Kartimo H, Mattila S, Tolonen A. 2006. Characterization of phenolic compounds from lingonberry (Vaccinium vitisidaea). J Agric Food Chem 54: 9834-9842. (Pubitemid 46158978)
8. Erlund I, Freese R, Marniemi J, Hakala P, Alfthan G. 2006. Bioavailability of quercetin from berries and the diet. Nutr Cancer 54: 13-17.
9. Farsi DA, Harris CS, Reid L, Bennett SA, Haddad PS, Martineau LC, Arnason JT. 2007. Inhibition of non-enzymatic glycation by silk extracts from a Mexican land race and modern inbred lines of maize (Zea mays). Phytother Res 22: 108-112. (Pubitemid 351155922)
10. Foo LY, Lu Y, Howell AB, Vorsa N. 2000. A-Type proanthocyanidi n trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod 63: 1225-1228.
11. Fraser M-H, Cuerrier A, Haddad P, Arnason JT, Owen P, Johns T. 2007. Medicinal plants of Cree communities (Québec, Canada): Antioxidant activity of plants used to treat Type 2 Diabetes symptoms. Canadian Journal of Physiology and Pharmacology 85: 1200-1214.
12. Harris CS, Burt AJ, Saleem A, Le PM, Martineau LC, Haddad PS, Bennett SA, Arnason JT. 2007. A single HPLC-PAD-APCI/MS method for the quantitative comparison of phenolic compounds found in leaf, stem, root and fruit extracts of Vaccinium angustifolium. Phytochem Anal 18: 161-169.
13. Hegele RA. 2001. Genes, environment and diabetes in Canadian aboriginal communities. Adv Exp Med Biol 498: 11-20.
14. Jellin J, Gregory PJ, Batz F, Hitchens K. 2005. Natural medicines comprehensive database. Therapeutic Research Faculty: Stockton.
15. Kahkonen MP, Hopia AI, Heinonen M. 2001. Berry phenolics and their antioxidant activity. J Agric Food Chem 49: 4076-4082.
16. Kari PR. 1985. Upper Tanana Ethnobotany. Alaska Historical Commission, Anchorage.
17. Leduc C, Coonishish J, Haddad P, Cuerrier A. 2006. Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: A novel approach in quantitative ethnobotany. J Ethnopharmacol 105: 55-63.
18. Lichtenthaler R, Marx F. 2005. Total oxidant scavenging capacities of common European fruit and vegetable juices. J Agric Food Chem 53: 103-110.
19. Marles RJ, Clavelle C, Monteleone L, Tays N, Burns D. 2000. Aboriginal plant use in Canada's northwest Boreal Forest. UBC Press: Vancouver.
20. Marshall S, Diamond L, Blackned S. 1989. Healing ourselves, helping ourselves: The medicinal use of plants and animals by the people of Waskaganish, Cree Regional Authority, Val d'Or, Quebec.
21. Martineau LC, Couture A, Spoor D, Benhaddou-Andaloussi A, Harris C, Meddah B, Leduc C, Burt A, Vuong T, Mai Le P, Prentki M, Bennett SA, Arnason JT, Haddad PS. 2006. Antidiabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait. Phytomedicine 13: 412-423.
22. Matsuda H, Wang T, Managi H, Yoshikawa M. 2003. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg Med Chem 11: 5317-5323.
23. McCune LM, Johns T. 2002. Antioxidant activity in medicinal plants associated with the symptoms of diabetes mellitus used by the indigenous peoples of the North American boreal forest. J Ethnopharmacol 82: 197-205. (Pubitemid 35292047)
24. Moerman D. 1998. Native American Ethnobotany. Timber Press: Portland.
25. Peyroux J, Sternberg M. 2006. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol Biol (Paris) 54: 405-419. (Pubitemid 44468299)
26. Ramasamy R. 2006. Glycation and RAGE: Common links in the pathogenesis of microvascular and macrovascular complications of diabetes. Canadian Journal of Diabetes 30: 422-429. (Pubitemid 44953760)
27. Rice-Evans CA, Miller NJ, Paganga G. 1996. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20: 933-956. (Pubitemid 26157509)
28. Rizzi G. 2003. Free radicals in the Maillard Reaction. Food Reviews International 19: 375-395.
29. Rosch D, Bergmann M, Knorr D, Kroh LW. 2003. Structure-antioxidant efficiency relationships of phenolic compounds and their contribution to the antioxidant activity of sea buckthorn juice. J Agric Food Chem 51: 4233-4239.
30. Schleicher ED, Wagner E, Nerlich AG. 1997. Increased accu mulation of the glycoxidation product N(epsilon)- (carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468. (Pubitemid 27414803)
31. Sheetz MJ, King GL. 2002. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Jama 288: 2579-2588.
32. Spoor DC, Martineau LC, Leduc C, Benhaddou-Andaloussi A, Meddah B, Harris C, Burt A, Fraser MH, Coonishish J, Joly E, Cuerrier A, Bennett SA, Johns T, Prentki M, Arnason JT, Haddad PS. 2006. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. Can J Physiol Pharmacol 84: 847-858.
33. Suzuki R, Okada Y, Okuyama T. 2003. Two flavone C-glycosides from the style of Zea mays with glycation inhibitory activity. J Nat Prod 66: 564-565. (Pubitemid 36531914)
34. Thornalley PJ, Langborg A, Minhas HS. 1999. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(1): 109-116.
35. Tunon H, Olavsdotter C, Bohlin L. 1995. Evaluation of antiinflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J Ethnopharmacol 48: 61-76.
36. Unoki H, Yamagishi S. 2008. Advanced glycation end products and insulin resistance. Curr Pharm Des 14: 987-989. (Pubitemid 351753287)
37. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL. 2003. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 29: 44-52.
38. Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053. (Pubitemid 38579764)
39. Wright JS, Johnson ER, DiLabio GA. 2001. Predicting the activity of phenolic antioxidants: theoretical method, analysis of substituent effects, and application to major families of antioxidants. J Am Chem Soc 123: 1173-1183.
40. Wu CH, Yen GC. 2005. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation end-products. J Agric Food Chem 53: 3167-3173.
41. Yamabe N, Kang KS, Goto E, Tanaka T, Yokozawa T. 2007. Beneficial effect of Corni fructus, a constituent of Hachimijio- gan, on advanced glycation end-product-mediated renal injury in Streptozotocin-treated diabetic rats. Biol Pharm Bull 30: 520-526.
42. Young TK, Reading J, Elias B, O'Neil JD. 2000. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress. CMAJ 163: 561-566.
43. Yu CH, Zinman B. 2007. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: A global perspective. Diabetes Res Clin Pract 78: 159-170.
44. Zheng W, Wang SY. 2003. Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. J Agric Food Chem 51: 502-509.
45. Zieba RA. 1992. Healing and healers among the northern Cree. National Library of Canada: Ottawa; 197.